Bristol-Myers upgraded at Leerink
Leerink Partners, the health-care advisory firm, has continued a recent recruitment drive with hires from boutiques ...
Leerink downgraded 908 Devices (MASS) to Market Perform from Outperform with a price target of $4, down from $12. Though the firm still sees ...
Fintel on MSN17h
Leerink Partners Downgrades 908 Devices (MASS)Fintel reports that on November 13, 2024, Leerink Partners downgraded their outlook for 908 Devices (NasdaqGM:MASS) from ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on November 12. The company’s ...
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 17.28% ...
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...
Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) – Leerink Partnrs cut their FY2024 EPS estimates for Celldex ...
Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical ...
We don't know how successful it will be, but also note that this is a serious competitive threat being introduced to the ...
Leerink notes that Syndax (SNDX) has disclosed topline pivotal data for menin-MLL inhibitor revumenib in NPM1m acute leukemia, which the firm ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback